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Lipid nanoparticles (LNPs) are currently the most effec-
tive in vivo delivery systems for silencing target genes in 
hepatocytes employing small interfering RNA. Antigen-
presenting cells (APCs) are also potential targets for LNP 
siRNA.  We  examined  the  uptake,  intracellular  traffick-
ing, and gene silencing potency in primary bone mar-
row macrophages (bmMΦ) and dendritic cells of siRNA 
formulated in LNPs containing four different ionizable 
cationic lipids namely DLinDAP, DLinDMA, DLinK-DMA, 
and  DLinKC2-DMA.  LNPs  containing  DLinKC2-DMA 
were the most potent formulations as determined by 
their ability to inhibit the production of GAPDH target 
protein. Also, LNPs containing DLinKC2-DMA were the 
most potent intracellular delivery agents as indicated by 
confocal studies of endosomal versus cytoplamic siRNA 
location using fluorescently labeled siRNA. DLinK-DMA 
and  DLinKC2-DMA  formulations  exhibited  improved 
gene silencing potencies relative to DLinDMA but were 
less toxic. In vivo results showed that LNP siRNA sys-
tems containing DLinKC2-DMA are effective agents for 
silencing GAPDH in APCs in the spleen and peritoneal 
cavity  following  systemic  administration.  Gene  silenc-
ing in APCs was RNAi mediated and the use of larger 
LNPs resulted in substantially reduced hepatocyte silenc-
ing, while similar efficacy was maintained in APCs. These 
results are discussed with regard to the potential of LNP 
siRNA formulations to treat immunologically mediated 
diseases.
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04 October 2011. doi:10.1038/mt.2011.190
IntroductIon
The therapeutic potential of siRNA-based drugs is considerable 
because they could allow selective gene silencing in vivo with high 
specificity and potency. However, effective delivery to targeted cells 
or tissues in vivo remains a major challenge.1 Cationic lipid-nucleic 
acid complexes have advantages of low immunogenicity and ease 
of manufacture as compared to viral delivery systems;2–4 however, 
they have limited use as systemic agents in vivo due to rapid clear-
ance and toxicity issues. Well-defined lipid nanoparticle (LNP) 
systems containing encapsulated nucleic acid and utilizing ioniz-
able cationic lipids to achieve long circulation lifetimes are more 
suited to in vivo applications.5–7 Recent in vivo studies have dem-
onstrated increasingly potent LNP delivery systems for silencing 
target genes in hepatocytes following systemic (intravenous, i.v.) 
injection,8–13 resulting in systems with significant gene silencing at 
dose levels as low as 30 μg siRNA per kg body weight.
The  major  variable  leading  to  increased  potency  of  LNP 
siRNA delivery systems for gene silencing in hepatocytes has been 
improvements in the cationic lipid employed.13 The cationic lipid 
is a critical component as a positively charged lipid is required 
to associate nucleic acid polymers with lipid-based delivery sys-
tems.14–16 A positive charge on the carrier also promotes asso-
ciation with the negatively charged cell membrane to enhance 
cellular uptake.17–19 In addition, it has been noted that cationic 
lipids combine with negatively charged lipids to induce nonbi-
layer  structures  that  facilitate  intracellular  delivery.20  Because 
charged LNPs are rapidly cleared from the circulation following 
i.v. injection,21–23 work in our laboratory has focused on the devel-
opment of ionizable cationic lipids with pKa values below 7.6,7 
Negatively  charged  polymers  such  as  siRNA  oligonucleotides 
can then be loaded into LNPs at low pH values (e.g., pH 4) where 
the ionizable lipids display a positive charge. However, at physi-
ological pH values, the LNPs exhibit a low surface charge com-
patible  with  longer  circulation  times.  Recent  work13  has  been 
focused  on  four  species  of  ionizable  cationic  lipids,  namely 
1,2-dilineoyl-3-dimethylammonium-propane  (DLinDAP), 
1,2-dilinoleyloxy-3-N,N-dimethylaminopropane  (DLinDMA), 
1,2-dilinoleyloxy-keto-N,N-dimethyl-3-aminopropane  (DLinK-
DMA),  and  1,2-dilinoleyl-4-(2-dimethylaminoethyl)-[1,3]-
dioxolane (DLinKC2-DMA). It has been shown that LNP siRNA 
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systems  containing  these  lipids  exhibit  remarkably  different 
gene silencing properties in hepatocytes in vivo, with   potencies 
varying  according  to  the  series  DLinKC2-DMA>DLinK-
DMA>DLinDMA>>DLinDAP  employing  a  Factor  VII  gene 
silencing model.13
It is of obvious interest to extend these studies to extrahepatic 
targets. Cells of the immune system are attractive target tissues 
because LNP systems are preferentially accumulated by the fixed 
and free monocytes of the reticuloendothelial system following i.v. 
or subcutaneous (s.c.) administration.24–27 Potential applications 
include treatment of inflammatory and autoimmune diseases that 
require silencing of genes in antigen-presenting cells (APCs).28–31
The  objective  of  this  study  was  to  assess  the  gene  silenc-
ing potency of LNP siRNA systems in primary APCs (pAPCs), 
namely  macrophages  (MΦ)  and  dendritic  cells  (DCs),  using 
LNP-siRNA  formulations  containing  DLinDAP,  DLinDMA, 
DLinK-DMA, and DLinKC2-DMA. We demonstrate that LNP 
containing DLinKC2-DMA is most effective producing a signifi-
cant siRNA-mediated GAPDH gene silencing in vitro in APCs at 
1 μg/ml levels. Further, it is demonstrated that intravenous admin-
istration of LNP GAPDH-siRNA systems containing DLinKC2-
DMA significantly inhibit the expression of GAPDH and CD45 
protein in vivo in spleen and peritoneal MФ and DCs. APC gene 
silencing is RNAi mediated as evidenced by 5′-RACE performed 
on peritoneal MФ samples. In addition, it is demonstrated that by 
increasing LNP size, LNP can be effectively redirected to APCs 
from liver tissue.
results
lnP containing dlinKc2-dMA exhibits the most 
potent sirnA-mediated gene silencing in vitro 
in primary APcs
Primary  bone  marrow  MΦ  (bmMΦ)  and  bone  marrow  DCs 
(bmDCs) were isolated as indicated under Methods and incu-
bated with 1 and 5 μg siRNA/ml scrambled or GAPDH-specific 
siRNA in LNP containing DLinDAP, DLinDMA, DLinKMA, and 
DLinKC2-DMA for 72 hours. Following treatment, GAPDH and 
control  α-Tubulin  expression  was  assessed  using  western  blot 
analysis and flow cytometry. In bmMΦ treated with 1 μg/ml LNP 
siRNA, significant GAPDH silencing (>60%) was only observed 
for LNP containing DLinKC2-DMA. (Figure 1a). At dose levels 
of 5 μg/ml, LNPs containing DLinKC2-DMA were again the most 
potent gene silencing agents (80%). At this dose level, LNPs con-
taining DLinDMA and DLinK-DMA also produced significant 
silencing (~60%), and DLinDAP was again ineffective.
Treatment  of  bmDCs  with  LNP-siRNA  resulted  in  more 
pronounced GAPDH silencing than in bmMΦ (Figure 1a). At 
dose levels of 1 μg/ml, GAPDH protein was significantly reduced 
72 hours after treatment with 1 μg/ml siRNA formulated in LNPs 
containing DLinDMA, DLinK-DMA, and DLinKC2-DMA, rela-
tive to the scramble control. The potency was further enhanced 
by increasing the siRNA dose to 5 μg/ml, where LNPs contain-
ing DLinKC2-DMA exhibited the highest silencing effects (83%). 
The gene silencing characteristics of LNP siRNA systems were 
also  investigated  following  treatment  of  bone  marrow  APCs 
(bmAPCs) with 5 μg/ml siRNA for 72 hours where GAPDH pro-
tein expression was assessed by intracellular staining and analyzed 
by flow cytometry. In bmMΦ treated with siRNA encapsulated in 
LNPs containing DLinDMA, DLinK-DMA, or DLinKC2-DMA, 
the  percentage  of  cells  expressing  GAPDH  was  decreased  by 
2.7-,  3.5-,  and  fourfold,  respectively,  relative  to  scramble  con-
trols (Figure 1b). Similar results were obtained following treat-
ment of bmDCs where higher silencing potencies were observed 
(Figure 1b). Taken together, these data indicate that LNPs con-
taining DLinKC2-DMA were the most efficient formulation for 
producing significant siRNA-mediated GAPDH gene knockdown 
in vitro at concentrations as low as 1 μg/ml.
lnPs containing dlinKc2-dMA exhibit highest 
uptake into APcs
It  is  important  to  determine  why  LNPs  containing  DLinKC2-
DMA  exhibit  the  most  potent  gene  silencing  characteristics. 
Two possibilities are that LNPs containing this lipid accumulate 
to higher levels in bmAPCs or that DLinKC2-DMA more effec-
tively disrupts the endosomal membrane following uptake. As the 
fluorescence intensity of Cy3-labeled siRNA can be sensitive to 
breakdown by nucleases (P.J. Lin, unpublished results), the rela-
tive levels of uptake were measured by labeling LNPs with the 
lipid label SPDiO. Scrambled siRNA was encapsulated in SPDiO-
labeled  LNPs  containing  DLinDAP,  DLinDMA,  DLinK-DMA, 
and DLinKC2-DMA, and cellular uptake of siRNA and LNP lipid 
was monitored over 24 hours by measuring the fluorescence inten-
sity of Cy3 and SPDiO in bmAPCs (Figure 2b). For all incubation 
times tested, significantly more uptake of siRNA and LNP lipid in 
LNPs containing DLinDMA, DLinK-DMA, and DLinKC2-DMA 
was observed relative to LNPs containing DLinDAP, suggesting 
that inefficient cellular uptake was at least partly responsible for 
the low levels of silencing seen with DLinDAP. Also, in bmMΦ 
and bmDCs, significantly more cellular uptake (P = 0.014 and 
P = 0.011, P < 0.05) of DLinKC2-DMA was detected, compared to 
DLinDMA and DLinK-DMA.
lnPs containing dlinKc2-dMA exhibit the greatest 
cytoplasmic delivery of sirnA as determined by 
fluorescence microscopy
To examine the fate of siRNA following uptake of LNP siRNA, 
a  confocal  microscopy  study  was  undertaken  to  visualize  the 
intracellular  distribution  of  fluorescently  labeled  siRNA.  Cy5-
labeled siRNA was encapsulated in LNPs containing DLinDAP, 
DLinDMA, DLinK-DMA, and DLinKC2-DMA which were incu-
bated with bmMΦ and bmDCs at 2 μg/ml siRNA for 2 hours. The 
cells  were  subsequently  washed,  and  intracellular  Cy5-labeled 
siRNA was followed for 1, 2, 4, and 8 hours (Figure 3). Similar 
levels of Cy5 fluorescence were observed in bmAPCs treated with 
DLinDAP, DLinDMA, DLinK-DMA, and DLinKC2-DMA at the 
1-hour time point. However, after 8 hours, a lipid-dependent dif-
ference was observed in the intracellular distribution pattern of 
Cy5-siRNA  in  bmMΦ  and  bmDCs  (Figure  3a).  Fluorescently 
labeled siRNA delivered in LNPs containing DLinDAP exhibited 
a punctate pattern, characteristic of intracellular compartmental-
ization (Figure 3a). In contrast, siRNA delivered with DLinDMA 
LNPs showed a punctate pattern initially, and both a punctate and 
a diffuse distribution at later time points. siRNA delivered with 
DLinK-DMA  and  DLinKC2-DMA  exhibited  a  predominantly 2188  www.moleculartherapy.org  vol. 19 no. 12 dec. 2011     
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diffuse pattern even at early time points. The images of Figure 3a 
were quantified to assess the levels of siRNA-Cy5 fluorescence in 
the cytoplasm and in the punctate compartments following deliv-
ery with all LNPs tested (Figure 3b,c). This analysis revealed that 
both bmMΦ and bmDCs displayed mainly a punctate distribu-
tion of siRNA-Cy5 when treated with DLinDAP LNPs (P = 0.017, 
P < 0.05). LNPs containing DLinDMA, DLinK-DMA, and in par-
ticular DLinKC2-DMA delivered significantly more (P = 0.016,   
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Figure 1  effect of lnP composition on the sirnA-mediated silencing in APcs. (a) On day 8, bmMΦ and bmDCs were incubated with scrambled 
or anti-GAPDH siRNA encapsulated in LNPs at indicated doses, for 72 hours including PBS-treated control. Cells were lysed, and GAPDH and α-Tubulin 
expression was measured from protein extracts using SDS-polyacrylamide gel electrophoresis and western blotting following costaining with appro-
priate antibodies. The intensity and presence of the bands obtained were used to assess the efficacy and specificity of formulated siRNA. Blots are 
representative of three independent experiments. Data were quantified by assessing the relative intensity as calculated by dividing the absolute 
intensity of each sample band by the absolute intensity of the standard (loading control) and expressed as columns (mean ± SD, n = 3) shown beside 
each representative blot (* indicates P < 0.05). (b) The efficacy of LNP-siRNA was assessed following intracellular staining and analysis by flow cytom-
etry. bmMΦ and bmDCs were treated with 5 μg/ml LNP-siRNA and after 72 hours, cells were fixed, permeabilized, and costained with anti-GAPDH 
and α-Tubulin followed by anti-rabbit IgG Alexa-647 and anti-mouse IgG-PE. Samples were acquired using a LSRII flow cytometer, and GAPDH and 
α-Tubulin protein expression was assessed. Data represent duplicates samples (mean ±) from two independent experiments. APC, antigen-presenting 
cells; bmDC, bone marrow dendritic cell; bmMΦ, bone marrow macrophages; LNP, lipid nanoparticles; PBS, phosphate-buffered saline.
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Figure 2  Intracellular presence of sirnA in bmMΦ and bmdcs is dependent on the lnP composition. (a) bmMΦ and DCs were incubated with 
1 μg/ml LNP-siRNA labeled to Cy5 or (b) with 10 μg/ml scrambled containing SPDiO-labeled LNP for 2, 4, 6, 8, and 24 hours. Cells were harvested 
followed by intracellular siRNA-Cy5, and LNP-spDiO fluorescence was assessed by flow cytometry. The graphs depict percent increase (mean ± SD, 
n = 3) of mean fluorescence units (MFU) over time relative to untreated controls. Data are representative of three different experiments performed in 
triplicate (* indicates P < 0.05). bmDC, bone marrow dendritic cell; bmMΦ, bone marrow macrophages; LNP, lipid nanoparticles.2190  www.moleculartherapy.org  vol. 19 no. 12 dec. 2011     
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P < 0.05) siRNA to the cytosol (Figure 3b,c). Little or no Cy5-
siRNA could be visualized intracellularly when cells were incu-
bated with free siRNA at similar dose levels.
lnP sirnA systems deliver sirnA in APcs 
via endocytosis
To determine mechanisms of uptake and intracellular processing 
of LNP siRNA systems, primary bone marrow (BM)-derived MΦ 
and DCs were treated with 2 μg/ml LNP Cy5-siRNA for 2 hours, 
and internalized siRNA was chased for 0.5, 1, 2, 4, and 8 hours. 
Cells were stained with antibodies against early endosomes (EEA1) 
and  examined  under  immunofluorescence  confocal  micros-
copy (ICM) to visualize the presence of siRNA in the endocytic 
pathway over time (Figure 4). As indicated by the yellow color 
of the vesicular compartments obtained by overlapping of siRNA 
(red) and endosomes (green), the LNP-siRNA systems enter the 
APCs primarily through the endocytic pathway. Colocalization 
of LNP-siRNA with endosomes was detected at early time points 
in both cell types (Figure 4). In agreement with the results of 
the previous section, the fluorescent pattern of siRNA delivered 
by DLinDAP LNPs remained punctate whereas for bmMΦ and 
bmDCs treated with DLinDMA, DLinK-DMA, and DLinKC2-
DMA LNPs, cytoplasmic siRNA was observed after 2 hours of 
chase which increased after 4 hours of chase as indicated by the 
lack of colocalization of siRNA with EEA1 and increased cytosolic 
siRNA fluorescence (data not shown). Similar to earlier findings, 
Free siRNA
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siRNA-DLinDAP siRNA-DLinDMA siRNA-DLin-KDMA siRNA-DLinKC2-DMA
8 hours
a
siRNA-DLinDAP siRNA-
DLinDMA
Formulation
siRNA-
DLinKDMA
siRNA-DLinKC2
DMA
Punctate
Diffuse
120
100
80
60
40
20
0
%
 
F
l
u
o
r
e
s
c
e
n
t
 
i
n
t
e
n
s
i
t
y
*
*
b
siRNA-DLinDAPs iRNA-
DLinDMA
Formulation
siRNA-
DLinKDMA
siRNA-DLinKC2
DMA
Punctate
Diffuse
120
100
80
60
40
20
0
%
 
F
l
u
o
r
e
s
c
e
n
c
e
 
i
n
t
e
n
s
i
t
y
*
*
c
Figure 3  the intracellular pattern and distribution of sirnA are cationic lipid dependent. (a) bmMΦ and bmDCs were grown on glass cover-
slips, and siRNA-Cy5 encapsulated in indicated LNPs was added at 2 μg/ml for 2 hours. LNPs were washed off and siRNA distribution was visualized 
after 1, 2, 4, and 8 hours under an ICM with a ×60 objective. Data are representative of at least three images acquired and depict the intracellular 
distribution after 8-hour time point only. Bar = 5 μm. (b) Quantification of intracellular distribution of siRNA in bmMΦ and bmDCs. To examine 
the intracellular pattern of siRNA, “spots of interest” were drawn and fluorescence intensity was quantified as described in Materials and Methods. 
A minimum of three images were assessed for both (b) bmMΦ and (c) bmDCs. Graphs depict the mean value (±SD) expressed as average intensity 
units of ~30 cells obtained from multiple fields. Data are representative of two independent experiments (* indicates P < 0.05). bmMΦ, bone marrow 
macrophages; ICM, immunofluorescence confocal microscopy; LNP, lipid nanoparticles.Molecular Therapy  vol. 19 no. 12 dec. 2011  2191
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DLinK-DMA and particularly DLinKC2-DMA LNPs delivered 
siRNA more effectively into the cytosol than DLinDMA LNPs. 
After 8 hours of chase, a complete separation of diffuse red siRNA 
and green endosomes was observed indicating relatively complete 
release of siRNA from the endosomes. In contrast, for LNP siRNA 
systems containing DLinDAP, the siRNA remained either in the 
endosomes or in other vesicular compartments as observed for 
both primary APCs.
To determine the eventual fate of LNP siRNA, primary APCs 
were treated with LNP-encapsulated siRNA for 2 hours followed 
by  a  16-hour  chase.  Cells  were  then  stained  with  EEA1  and 
LAMP1 antibodies to visualize early endosomes and lysosomes, 
respectively. Intracellular localization of siRNA was visualized, 
and  the  presence  of  siRNA  in  endosomes  and  lysosomes  was 
quantified as described in Materials and Methods. The data dem-
onstrate that siRNA delivered by DLinDAP LNPs remained in 
endosomes and lysosomes as indicated by colocalization (yellow 
color) of siRNA (red) with EEA1+ endosomes (green), and lyso-
somes revealed by the overlapping (purple color) of siRNA (red) 
and LAMP1 (blue) (Figure 5a). In contrast, siRNA delivered with 
DLinDMA, DLinK-DMA, or DLinKC2-DMA showed typically a 
cytosolic distribution with only a small fraction detected in the 
endosomes or lysosomes (particularly in DCs) (Figure 5a). These 
results demonstrate that DLinDMA, DLinK-DMA, and in partic-
ular DLinKC2-DMA LNPs efficiently promote release of encapsu-
lated siRNA into the cytosol following uptake via the endocytotic 
pathway.
lnPs containing dlinKc2-dMA are relatively 
nontoxic to APcs
In order to test the influence of the LNP formulations on the 
viability of primary APCs, bmAPCs were treated with various 
doses of LNP-siRNA or free siRNA and after 72-hour incubation, 
apoptosis and necrosis were assessed (Supplementary Materials 
and Methods). LNPs containing DLinDAP, DLinK-DMA, and 
DLinKC2-DMA displayed almost no toxicity in primary APCs 
(Supplementary Figure S1) even at the highest doses tested (5 μg/
ml). LNPs containing DLinDMA, however, induced a significant 
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Figure 4  Influence of cationic lipid on endosomal escape of sirnA. Primary bmMΦ or bmDCs were treated with 2 μg/ml Cy5-siRNA encapsulated 
in LNPs as indicated, for 2 hours. LNP-siRNAs were washed off, and their localization was examined at 0.5, 1, 2, 4, and 8 hours under an ICM with a 
×60 objective following staining with anti-EEA1 antibody to visualize the presence of siRNA (red) in early endosomes (green). Data are representative 
of three to five images acquired from two independent experiments. Only 0.5- and 8-hour time points are shown. bmDC, bone marrow dendritic 
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increase in apoptotic cells even at doses as low as 1 μg/ml result-
ing in loss of cell viability (Supplementary Figures S1 and S2a). 
Treatment with LNPs containing DLinK-DMA and DLinKC2-
DMA  resulted  in  the  highest  levels  of  intracellular  siRNA  at 
72-hour post-treatment but exhibited little or no toxicity relative 
to DLinDMA-siRNA indicating that higher intracellular levels 
of siRNA did not result in increased toxicity. Overall, these data 
indicate that toxicity does not correlate with intracellular delivery 
and gene silencing potency and appears to be more directly asso-
ciated with the particular cationic lipid employed.
Biodistribution of lnP-sirnA and intracellular 
delivery in tissue resident APcs
We set out to investigate the biodistribution of Cy3-labeled siRNA 
formulated  with  the  LNPs  under  study,  30  minutes  after  sys-
temic administration (Supplementary Materials and Methods). 
Confocal  microscopy  analysis  revealed  that  fluorescence  was 
measurable in all tissues analyzed (Supplementary Figure S3a). 
However, the overall distribution was organ and LNP dependent. 
It was observed that liver was the organ that took up significant 
amount of siRNA followed by spleen (data not shown), lymph 
nodes (LNs), and BM. Detectable levels of siRNA were observed 
in heart while insignificant amounts were revealed in the lungs. 
Also, a smaller amount of siRNA was observed following delivery 
with DLinDAP as assessed by lower fluorescent signal that was 
more evident in the liver. To further assess the siRNA delivery to 
tissue resident APCs and other cell types, such as T cells (CD8+, 
CD4+) and B cells that are abundant in the lymphoid organs, Cy5-
siRNA was formulated with the best performing LNP and injected 
i.v. in mice. Flow cytometry analysis revealed that after 24 hours, 
Cy5-siRNA was measurable in liver, spleen, and LN APCs and less 
in the BM (Supplementary Figure S3b). In addition, very small 
amount of siRNA was measured in splenic CD19+ B cells, and 
no delivery could be detected in spleen or LN CD8+ and CD4+ 
T cells (Supplementary Figure S3c). Taken together, these data 
indicate that siRNA LNPs are taken up by several organs and that 
our most efficient LNP DLinKC2-DMA is capable of delivering a 
substantial amount of siRNA in MΦ and DCs in lymphoid tissues. 
However, distribution is not necessarily equivalent to silencing, as 
siRNA needs to reach cytoplasm for activity.
lnPs containing dlinKc2-dMA can induce gene 
silencing in APcs in vivo following i.v. injection
The previous studies have shown that LNPs containing GAPDH-
siRNA can induce gene silencing in primary APCs in vitro and that 
the most effective and least toxic formulations contain DLinKC2-
DMA. It is of obvious interest to determine whether such formula-
tions induce significant gene silencing in vivo following i.v. injection. 
Mice were dosed (5 mg/kg siRNA) with LNPs formulated employing 
DLinKC2-DMA and containing GAPDH-specific siRNA or control 
anti-FVII siRNA. APCs were harvested from peritoneal cavity and 
spleens 4 days later, and GAPDH expression was assessed in F4-80/
CD11b- and CD11c-enriched cell populations using flow cytom-
etry and western blotting. It was observed that treatment with LNP 
siGAPDH formulated with DLinKC2-DMA produced ~40% silenc-
ing  by  significantly  reducing  GAPDH  production  in  peritoneal 
cavity MΦ and DCs (P < 0.05) and in the spleen-derived APCs as 
assessed by flow cytometry (Figure 6a). GAPDH silencing was also 
assessed by western blot analysis and revealed significant potency 
of DLinKC2-DMA as judged   visually by the reduced GAPDH band 
in the APCs of each treated animal (Figure 6b). Quantification of 
the protein bands indicated that in spleen-derived APCs, GAPDH 
was reduced by 60% relative to siFVII control following systemic 
administration of DLinKC2-DMA-formulated siGAPDH whereas 
the expression levels of α-Tubulin were unchanged (Figure 6c). 
No substantial gene silencing was observed in LN APCs; in addi-
tion, siRNA delivery using the current systems failed to produce 
any silencing in B and T cells (data not shown). The discrepancy 
in gene silencing between spleen and LN APCs, however, could be 
partly explained by the overall difference in siRNA amount in these 
tissues determined by the blood supply and microenvironment. It 
could also be influenced by the heterogeneity of MΦ or DCs sub-
sets. It is important to note that no treatment-related gross toxic 
effects were observed as determined by monitoring the weight loss 
(Supplementary Figure S4). These data demonstrate that LNPs 
containing DLinKC2-DMA are efficient promoters of siRNA-medi-
ated gene silencing in vivo in spleen APCs.
Gene silencing in macrophages is rnAi mediated
To access whether the silencing observed in APCs was mediated by 
RNAi mechanism, cells of monocyte/macrophage lineage (CD11b 
positive) were purified from mice treated with CD45 siRNA11 encap-
sulated in the DLinKC2-DMA formulation; mRNA was isolated 
from these cells and subjected to rapid amplification of cDNA ends 
(5′-RACE), a method previously used to demonstrate that siRNA-
mediated cleavage occurs.12,32 5′-RACE analysis revealed products of 
the expected sizes for CD45 amplicon in samples treated with CD45 
specific but not with the control siRNA in the DLinKC2-DMA for-
mulation (Supplementary Figure S5). Sequence analysis of cloned 
PCR products demonstrated that 46 of 48 products contained pre-
dicted cleavage at position (CTGGCTGAA/TTTCAGAGCA) for 
CD45 siRNA in DLinKC2-DMA formulation. No specific cleav-
age sites were derived from the 5′-RACE samples treated with LNP 
encapsulated  control  siRNA  (of  48  sequenced  products).  These 
results clearly demonstrate that the effect of siRNA in LNP treat-
ment on CD45 expression level observed is consistent with cleavage 
of the mRNA transcript via a targeted RNAi mechanism.
designing sirnA lnP nanoparticles with differential 
activity in the liver and in APcs
As  the  standard  DLinKC2-DMA-based  LNPs  were  optimized 
for hepatic delivery of siRNA,13 it mediates silencing of genes in 
hepatocytes with considerably better efficiency than in APCs. It 
was of interest to explore whether more APC-specific silencing 
could be achieved by redirecting particles away from the liver. To 
accomplish this, we exploited the fact that macrophages encounter 
and efficiently internalize particles of variable sizes (from 50 nm 
to  10 μm),33  whereas  efficient  delivery  to  hepatocytes  is  likely 
restricted by the size of fenestrae in liver endothelium, estimated 
to be about 100–150 nm.34 To compare liver and APC delivery 
in the same experiment, LNPs were formulated containing siR-
NAs targeting Factor VII (FVII), a liver-specific gene and CD45, 
a pan-leukocyte marker. Three formulations with an average size 
of 80 (normal), 240 (medium), and 360 nm (large) were tested 2194  www.moleculartherapy.org  vol. 19 no. 12 dec. 2011     
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with identical composition. These formulations contained either 
CD45 siRNA or Luc/Factor VII (9:1) siRNA and were tested by 
i.v. bolus administration in naive C57BL/6 mice at 3 mg/kg (n = 3) 
(Figure 7a). A lower amount of Factor VII siRNA was used since 
the activity of the original formulation is about tenfold higher in 
hepatocytes relative to leukocytes; Luc siRNA was included in the 
Factor VII formulation to maintain the total dose of siRNA and 
LNPs constant for all experimental groups. Three days after injec-
tion, leukocytes were collected from the peritoneal cavity, and 
Factor VII was quantified from serum. Leukocytes were stained 
with antibodies for a combination of surface markers including 
CD45, F4-80, CD11b as a macrophage-specific marker. Silencing 
of  CD45  in  macrophages  is  identical  for  these  formulations 
(Figure 7b). However, reduction of serum FVII was decreased 
with increasing LNP size, consistent with decreased accessibility 
of larger LNPs through the liver fenestrae. Therefore, by utilizing 
larger LNPs, more APC-selective silencing may be achieved. We 
also set to investigate the duration of APC gene silencing in vivo 
using green fluorescent protein (GFP) transgenic mice. Data show 
that a marked suppression in GFP was observed in the peritoneal 
MΦ of siGFP-DLinKC2-DMA-treated mice 3 days following sys-
temic administration (Figure 7c). Peritoneal cells were isolated at 
day 3 post-injection and seeded in a culture dish. Gene silencing 
persisted for ~14 days after initial dose.
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treatment with dlinKc2-dMA produces insignificant 
amount of tnF-α in vitro and in vivo
The potential of transfected MΦ to produce TNF-α in response 
to  LNPs  as  a  readout  for  cell  stimulation  by  uptake  was  also 
studied. BmMΦ were incubated in vitro with different doses of 
siRNA formulated with the LNPs under study, or spleen MΦ of 
siRNA-DLinKC2-DMA-treated  mice  were  isolated  and  TNF-α 
expression was assessed intracellularly by flow cytometry. Various 
expression levels of TNF-α were observed in bmMΦ following 
in vitro incubation with siRNA LNPs, and DLinDMA was the 
most potent cytokine inducer (Figure 8a). However, little amount 
of  TNF-α  was  observed  following  DLinKC2-DMA  treatment 
which showed levels similar to the least toxic LNP we know, the 
DLinDAP. Remarkably, MΦ transfected in vivo with DLinKC2-
DMA  expressed  little  amount  of  TNF-α ( Figure  8b).  Taken 
together the data indicate that there is a potential that LNP-siRNA 
complexes may induce cytokines in a dose-dependent manner 
and that the most efficient formulation DLinKC2-DMA produced 
insignificant amount of TNF-α in MΦ in vivo.
In vivo-transfected dcs maintain their function to 
activate t cells and migrate in lymph nodes
To test functional properties of LNP-treated APC, we tested the 
ability of in vivo-transfected DCs to activate T cells following anti-
gen uptake (Supplementary Materials and Methods). For this, 
spleen DCs of mice injected with siRNA-DLinKC2-DMA were 
isolated, fed with ovalbumine, and their ability to activate the 
T-cell line B3Z35 was assessed and compared with the untreated 
DCs. Flow cytometry analysis revealed that there was no differ-
ence between control and in vivo-transfected DCs in their abil-
ity to activate T cells following cross-  presentation of ovalbumine 
antigen (Supplementary Figure S6a). Furthermore, the migra-
tion potential of in vivo-transfected GFP+ DCs was also tested 
and compared with control DCs following injection in the foot 
pad of C57Bl6 mice. It was observed that almost equal number 
of cells migrated to inguinal LNs from the injection site in con-
trol  and  siRNA-DLinKC2-DMA-treated  mice  (Supplementary 
Figure S6b). Overall, the data indicate that there is essentially no 
functional impairment of DCs following their in vivo transfection 
with DLinKC2-DMA-formulated siRNA.
dIscussIon
This  work  demonstrates  that  LNP  siRNA  systems  containing 
appropriate ionizable cationic lipids can induce significant silenc-
ing of the “marker” target gene GAPDH for primary APCs both 
in vitro and in vivo. There are three aspects of these results that 
warrant further discussion, including the reasons why LNPs con-
taining DLinKC2-DMA exhibit superior gene silencing potencies 
in vitro for APCs, the significance of the observation that LNP 
siRNA  systems  containing  DLinKC2-DMA  are  effective  gene 
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silencing agents for MФ and DCs in vivo together with poten-
tial  ways  in  which  the  activity  could  be  improved  and  finally 
the potential applications of LNP siRNA systems that are able to 
silence genes in immune cells.
The  results  presented  indicate  that  LNP  siRNA  systems 
containing  DLinKC2-DMA  are  the  most  potent  formulations 
for  achieving  silencing  of  GAPDH  in  MФ  and  DCs  in  vitro. 
These results are similar to behavior noted for LNP siRNA sys-
tems  for  FVII  gene  silencing  in  vivo13  where  it  was  observed 
that the potency varied according to DLinKC2-DMA> DLinK-
DMA>DLinDMA>DLinDAP following i.v. injection. The in vitro 
results presented here indicate similar activities, with the excep-
tion that LNPs containing DLinDMA were somewhat more effec-
tive than LNPs containing DLinK-DMA for GAPDH silencing 
(Figure 1). The relative ineffectiveness of the DLinDAP formula-
tions could be partly related to rapid hydrolysis in the endosome 
of the labile ester linkages present in this cationic lipid (P.J. Lin, 
unpublished results). Hydrolysis of DLinDAP will reduce disrup-
tion of the endosomal membrane, therefore siRNA release into the 
cytoplasm, as well as expose encapsulated siRNA to potential deg-
radation by endogenous nucleases in the endosome.36 However, it 
is also clear that the levels of uptake of the DLinDAP-containing 
systems are much lower than for LNPs containing other cationic 
lipids (Figure 2). Further, it is also obvious that after accumula-
tion, LNPs containing DLinDAP are much less effective agents for 
facilitating endosomal escape of encapsulated siRNA as evidenced 
by the very low diffuse-to-punctate ratio for accumulated siRNA 
for these systems (Figure 3). LNPs containing DLinKC2-DMA 
are accumulated at higher levels than LNPs containing DLinDMA 
or DLinK-DMA for both MФ and DCs (Figure 2) which likely 
accounts for the higher gene silencing activity noted for these for-
mulations. Similarly, LNPs containing DLinDMA and DLinKC2-
DMA are accumulated to approximately similar levels and exhibit 
about the same levels of silencing potency. It is interesting to note, 
however, that the siRNA intracytoplasmic delivery capability of 
LNPs containing DLinKC2-DMA is considerably improved over 
those containing DLinDMA as indicated by the low punctate-to-
diffuse ratio observed for the DLinKC2-DMA system (Figure 3), 
which would also be expected to enhance silencing potency.
The second area of discussion concerns the significance of the 
observation that LNP siRNA systems containing DLinKC2-DMA 
can silence genes in spleen and peritoneal cavity MФ and DCs as 
well as ways in which the transfection potency of the LNP systems 
employed here could be improved. There have been a variety of 
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reports demonstrating gene silencing in APCs following i.v. admin-
istration of siRNA in free or encapsulated form. Free siRNA can 
result in silencing of liver MФ following hydrodynamic (high vol-
ume) tail vein (HTV) injection of siRNA.37–39 However, aside from 
providing proof of concept on the effectiveness of siRNA in vivo 
to inhibit endogenous genes, there are drawbacks to this method 
that make its application in clinical practice unlikely. In addition 
to a transient toxicity, the use of HTV injection results in delivery 
of siRNA primarily to the liver. A variety of nanoparticle delivery 
approaches have been described such as targeting of siRNA to MΦ40 
using glucan-encapsulated siRNA particles (GeRPs), integrin-tar-
geted stabilized nanoparticles (I-tsNPs) for leukocytes41, and immu-
noliposomes for DCs.42 However, all these methods have limitations. 
For example, despite the advantage of ease of oral administration for 
the GeRPs, APC transfection is relatively inefficient. Similarly, the 
finding that following systemic administration, I-tsNPs were pref-
erentially accumulated in the gut, suggests primarily tissue-specific 
indications. Zheng and colleagues42 have employed imunoliposomes 
conjugated to DC-specific antibody for targeting CD40 on DCs. 
A possible disadvantage of this approach for clinical applications 
is that chimeric antibodies as targeting agents have been reported 
to elicit immune responses and could contribute to unpredictable 
side effects.43,44 The LNP system employed here exhibits a number of 
advantages over previous methods, including high siRNA encapsu-
lation efficiencies (>95%), relatively low toxicity in vitro and in vivo 
as indicated by parameters such as weight loss, no impairment of 
DC antigen presentation and migration, as well as minute induction 
of cytokines, particularly for the best performing LNP, in addition 
to the ability to silence APCs in anatomically distant locations such 
as peritoneal cavity and spleen.
It is likely that improvements to the LNP siRNA systems out-
lined here will be possible. By way of comparison, similar LNP 
siRNA systems have recently been demonstrated to achieve gene 
silencing in hepatocytes following i.v. administration at dose   levels 
as low as 30 μg siRNA/kg body weight.13 The improved potency 
of these systems as compared to the dose levels of 5 mg siRNA/
kg body weight employed here stems from at least two factors. 
First, Semple and colleagues13 employed higher levels of cationic 
lipid and lower levels of PEG-lipids and it is expected that signifi-
cantly improved potency will be observed for silencing genes in 
APCs when such formulations are employed. Second, it has also 
been demonstrated that LNP-induced gene silencing in hepato-
cytes benefits from stimulated uptake due to association of ApoE 
with the LNP particles following i.v. injection.45 It is likely that 
the inclusion of ligands that stimulate uptake into APCs will bring 
similar benefits to gene silencing in immune cells. Alternatively, 
the strategy of increasing LNP size can also improve APC-specific 
silencing as demonstrated here.
There are many potential applications for LNP siRNA systems 
that can silence genes in APC and we only point out three of them 
here. First, inactivation of CD45 correlates with long-term engraft-
ment of allogeneic and xenogeneic heart and kidney transplants,46 
whereas  in  patients  with  Alzheimer’s  disease  CD45  expression 
is upregulated on microglia cells.47 Thus, targeting CD45 in MΦ 
using LNP-siRNA has direct applicability to clinical transplanta-
tion, treatment of autoimmune diseases or neuroinflammation 
associated with Alzheimer’s disease.48 Second, silencing CD40 in 
DCs could be an effective method for minimizing   autoimmune 
responses  by  inducing  antigen-specific  immune  suppression.42 
Finally,  RNAi  techniques  may  be  useful  to  improve  cancer 
immuno  therapies. Immune activation in the tumor microenvi-
roinment combined with siRNA that targets immune suppressor 
genes in tumor-infiltrating APCs represents a potentially effective 
approach for cancer immunotherapy.49
MAterIAls And Methods
Preparation  of  LNPs  and  siRNA  encapsulation.  The  cationic  lipids 
1,2-dilineoyl-3-dimethylammonium-propane  (DLinDAP),  1,2-dilinol-
eyloxy-3-N,N-dimethylaminopropane  (DLinDMA),  1,2-dilinoleyloxy- 
keto-N,N-dimethyl-3-aminopropane (DLinK-DMA), 1,2-dilinoleyl-4-(2- 
dimethylaminoethyl)-[1,3]-dioxolane (DLinKC2-DMA), (3-o-[2″-(meth 
oxypolyethyleneglycol  2000)  succinoyl]-1,2-dimyristoyl-sn-glycol 
(PEG-S-DMG),  and  R-3-[(ω-methoxy-poly(ethylene  glycol)2000)
carbamoyl]-1,2-dimyristyloxlpropyl-3-amine  (PEG-C-DOMG)  were 
provided by Tekmira Pharmaceuticals (Vancouver, Canada) or synthe-
sized as described elsewhere.13 Cholesterol was purchased from Sigma 
(St Louis, MO). The anti-Factor VII Cy5-labeled siRNA was provided 
by Alnylam Pharmaceuticals (Cambridge, MA) and was used in a free 
form  or  was  encapsulated  in  LNPs  containing  DLinDAP,  DLinDMA, 
DLinK-DMA, and DLinKC2-DMA (cationic lipid:DSPC:CHOL: PEG-
S-DMG or PEG-C-DOMG at 40:10:40:10 molar ratios). When required, 
0.2%  SP-DiOC18  (Invitrogen,  Burlington,  Canada)  was  incorporated 
to assess cellular uptake, intracellular delivery, and biodistribution. For 
gene silencing experiments, anti-GAPDH siRNA (siGAPDH) was pur-
chased  from  Dharmacon.  The  preformed  vesicle  method  of  siRNA 
encapsulation was employed as described elsewhere.6–7,13 Briefly, the lipid 
mixtures  comprised  of  cationic  lipid:DSPC:cholesterol:PEG-c-DOMG 
(40:10:40:10 molar ratio) were dissolved in ethanol to a final lipid concen-
tration of 10 mmol/l. This ethanol solution of lipid was added drop-wise 
to 50 mmol/l citrate, pH 4.0 to form multilamellar vesicles to produce 
a final concentration of 30% ethanol vol/vol. Large unilamellar vesicles 
were  formed  following  extrusion  of  multilamellar  vesicles  through 
two stacked 80 nm Nuclepore polycarbonate filters using the Extruder 
(Northern Lipids, Vancouver, Canada). Encapsulation was achieved by 
adding siRNA dissolved at 2 mg/  ml in 50 mmol/l citrate, pH 4.0 contain-
ing 30% ethanol vol/vol drop-wise to extruded preformed large unilamel-
lar vesicles and incubation at 31 °C for 30 minutes with constant mixing to 
a final siRNA/lipid weight ratio of 0.06/1 wt/wt. Removal of ethanol and 
neutralization of formulation buffer were performed by dialysis against 
phosphate-buffered saline (PBS), pH 7.4 for 16 hours using Spectra/Por 2 
regenerated cellulose dialysis membranes. Nanoparticle size distribution 
was determined by dynamic light scattering using a NICOMP 370 particle 
sizer, the vesicle/intensity modes, and Gaussian fitting (Nicomp Particle 
Sizing, Santa Barbara, CA). The particle size for all three LNP systems 
was ~70 nm in diameter. siRNA encapsulation efficiency was determined 
by removal of free siRNA using VivaPureD MiniH columns (Sartorius 
Stedim Biotech) from samples collected before and after dialysis. The 
encapsulated siRNA was then extracted from the eluted nanoparticles and 
quantified at 260 nm. siRNA to lipid ratio was determined by measure-
ment of cholesterol content in vesicles using the Cholesterol E enzymatic 
assay from Wako Chemicals USA (Richmond, VA).
Preparation of large LNPs. A lipid premix solution (20.4 mg/ml total lipid 
concentration) was prepared in ethanol containing DLinKC2-DMA, DSPC, 
and cholesterol at 50:10:38.5 molar ratios. Sodium acetate was then added 
to the lipid premix at a molar ratio of 0.75:1 (sodium acetate:DLinKC2-
DMA). The lipids were subsequently hydrated by combining the mixture 
with 1.85 volumes of citrate buffer (10 mmol/l, pH 3.0) with vigorous stir-
ring, resulting in spontaneous liposome formation in aqueous buffer con-
taining 35% ethanol. The liposome solution was then incubated at 37 °C to 2198  www.moleculartherapy.org  vol. 19 no. 12 dec. 2011     
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allow for time-dependent increase in particle size. Aliquots were removed 
at various times during incubation to investigate changes in liposome size 
by dynamic light scattering (Zetasizer Nano ZS, Malvern Instruments, 
Worcestershire, UK). Once the desired particle size was achieved, an aque-
ous PEG lipid solution (stock = 10 mg/ml PEG-DMG in 35% (vol/vol) 
ethanol) was added to the liposome mixture to yield a final PEG molar 
concentration of 3.5% of total lipid. Upon addition of PEG-lipids, the lipo-
somes maintained their size, effectively quenching further growth. siRNA 
was then added to the empty liposomes at an siRNA to total lipid ratio of 
approximately 1:10 (wt:wt), followed by incubation for 30 minutes at 37 °C 
to form loaded LNPs. The mixture was subsequently dialyzed overnight in 
PBS and filtered with a 0.45-μm syringe filter.
Cell culture of primary APCs. bmAPCs were prepared from BM progenitors 
by flushing 6- to 8-week-old C57BL/6 (Jackson Laboratory) mouse femurs 
and tibias with PBS. After 2 washes, BM-derived progenitor cells were cul-
tured in 6-well plates at 2 × 106 cells/ml in 5 ml in complete medium (RPMI 
1640 supplemented with 2 mmol/l L-glutamine, 100 U/  ml penicillin, 100 μg 
streptomycin, 10% fetal calf serum, sodium pyruvate (1 mmol/l), nones-
sential aminoacids (1 mmol/l), and Hepes (10 mmol/l) all from Invitrogen 
supplemented with either 10% 1x L929 cell conditioned media for differ-
entiation of MΦ or X63-Ag8-plasmacytoma-derived GM-CSF (gift from 
David Gray, University of Edinburgh, Edinburgh, UK) 80 μl/5 ml for DCs. 
On day 8, bmMΦ were stained with antibodies against I-Ab (AF6.120.1) 
and CD11b whereas bmDCs were stained with H-2Kb (AF6.88), I-Ab, 
CD11c (HL3) (Pharmingen), and DEC-205 to assess their purity and stage 
of maturation. All cells were cultured in a humidified atmosphere of 5% 
CO2 at 37 °C. After 8 days of culture, more then 80% of cells expressed MΦ- 
and DC-specific markers, respectively, as determined by flow cytometry.
Silencing of APCs in vitro. The day prior to treatment, bmMΦ and bmDCs 
were washed and replenished with fresh media in the original plates. SiRNA 
against  GAPDH  (sense  sequence:  UGGCCAAGGUCAUCCAUGA)  or 
negative control scrambled siRNA encapsulated in DLinDAP, DLinDMA, 
DLinK-DMA, and DLinKC2-DMA LNPs was added on day 8 of culture 
at 1 and 5 μg/ml final concentration and incubated for 72 hours at 37 °C 
and 5% CO2. In each experiment, one well was treated PBS and served as 
a negative control. The media was changed every other day while the con-
centration of siRNA was maintained at required concentrations. Following 
treatment, GAPDH and α-Tubulin protein expression was measured to 
assess the efficacy and specificity of formulated siRNA.
Western blotting: Adherent bmMΦ were washed with cold PBS in 
the original plate followed by addition of RIPA lysis buffer containing 
1% Nonidet P-40 (NP-40), 120 mmol/l NaCl, 4 mmol/l MgCl2, 20 mmol/l 
Tris-HCl  pH  7.6,  protease  inhibitor  cocktail  (Roche)  1 mmol/l  PMSF 
and NaF, and incubated for 45 minutes at 4 °C. Cells were harvested by 
scraping  the  adherent  cells  with  a  cell-scraper.  Cell  lysates  were  then 
transferred in to a microcentrifuge tube and spun at maximum speed for 
10 minutes. Floating bmDCs were washed 1 x with cold PBS and lysed 
by resuspending and incubating in RIPA lysis buffer for 45 minutes. The 
lysates were spun for 10 minutes at maximum speed at 4 °C, and protein 
concentration was assessed using Bradford assay (Biorad). About 5 μg 
protein  sample  was  resuspended  in  appropriate  volume  of  10%  SDS-
containing Laemmli buffer and boiled for 5 minutes at 100 °C. Samples 
were subsequently analyzed on a 10% gradient SDS-polyacrylamide gel 
electrophoresis  (PAGE).  The  gel  was  transferred  onto  a  nitrocellulose 
membrane  (PallCorporation,  Pensacola,  FL),  blocked  with  Odyssey 
Blocking Buffer (Li-cor Biosciences, Lincoln, NE) and costained with 
rabbit anti-GAPDH and mouse anti α-Tubulin antibodies (Santa Cruz 
Biotechnology,  Santa  Cruz,  CA)  at  1:200  dilution  overnight.  IRDye 
680CW donkey anti-rabbit IgG (H+L) and IRDye 800CW donkey anti-
mouse  IgG  (H+L)  (Li-Cor  Biosciences)  were  used  at  1:2000  dilution 
to  detect  the  GAPDH  and  α-Tubulin,  respectively,  following  2-hour 
incubation  in  the  dark.  Blots  were  scanned  on  an  Odyssey  Infrared 
Imaging System to visualize the bands of interest. Images were acquired 
at medium intensity and resolution 3. Quantification of the data was 
performed using Photoshop 9.0 CS2 software. Absolute intensity for each 
selected sample band was obtained by multiplying the pixel value with the 
average intensity. The relative intensity was then calculated by dividing 
the absolute intensity of each sample band by the absolute intensity (pixel 
value × average intensity) of the standard (loading control).
Flow cytometry: The efficacy of formulated siRNA was also determined 
by intracellular staining and assessment with flow cytometry. For this, 72 
hours  following  treatment  with  5 μg/ml  siGAPDH  or  scramble  control 
formulated  with  the  LNPs  under  study,  bmMΦ  and  bmDCs  were 
harvested, transferred into microcentrifuge tubes and spun at 12,000 for 
4 minutes. Cells were washed twice with FACS staining buffer (2% FBS, 
1 mmol/l EDTA, and 0.1% Na Azide) and resuspended in fixation buffer 
(paraformaldehyde  4%)  for  20  minutes.  Next,  they  were  resuspended 
in  permeabilization  buffer  (saponin  0.5%,  Sigma  Aldrich,  St.  Louis, 
MO), aliquoted, and costained with rabbit anti-GAPDH and mouse anti 
α-Tubulin antibodies at 1:20 dilution for 30 minutes at room temperature. 
After two washings with permeabilization buffer, cells were labeled with 
goat anti-rabbit IgG (H+L) Alexa-647 (Invitrogen) and goat anti-mouse 
IgG (H+L) PE-conjugated antibodies in the dark, to detect the GAPDH 
and α-Tubulin, respectively, in bmAPCs. Unstained and cells incubated 
with isotype controls were included in all experiments. Next, bmAPCs 
were washed extensively with permeabilization buffer and PBS, followed 
by resuspension in 300 μl FACS staining buffer prior to data acquisition. 
The LSRII flow cytometer (BD Biosciences, San Jose, CA) and FACSDiva 
software were used to measure protein expression following acquisition of 
10,000 events. Data were analyzed by FlowJo software. GAPDH expression 
values were normalized against α-Tubulin and expressed as percent reduced 
fluorescence relative to scramble control that was considered 100%.
Intracellular delivery of siRNA by LNPs. On day 8, bmMΦ and bmDCs 
were transferred to 24-well plates, treated with 1 μg/ml siRNA-Cy5 in a 
free form or encapsulated in DLinDAP, DLinDMA, DLinK-DMA, and 
DLinKC2-DMA LNPs, and maintained at 37 °C. Incubation was stopped 
by washing off the media and harvesting the cells after 2, 4, 6, 8, and 24 
hours. Cells were also incubated with 0.5, 1, or 5 μg/ml Cy5-labeled siRNA 
for 24 hours to assess the dose-dependent intracellular delivery of siRNA. 
To investigate whether the intracellular bioavailability of siRNA in bmAPCs 
correlates with the cellular uptake of LNPs, in parallel scrambled siRNA 
was formulated with DLinDAP, DLinDMA, DLinK-DMA, and DLinKC2-
DMA labeled with spDiO and incubated with bmAPCs for the same time, 
at 10 μg/ml. Incubation was stopped in the same fashion after the same time 
intervals. Following treatment, bmAPCs were transferred into microcen-
trifuge tubes, spun at 12,000 rpm for 4 minutes and after three washes, they 
were resuspended in 300 μl FACS staining buffer. Samples were acquired 
using an LSRII flow cytometer to assess the presence of Cy5-labeled siRNA 
as well as spDiO-labeled LNPs intracellularly. The Cy5 fluorophore was 
excited using the HeNe 633 laser line and detected at the APC (FL 5) chan-
nel whereas the spDiO by the Argon laser and detected at FL1 channel. 
Data were acquired using FACSDiva software and analyzed by FlowJo soft-
ware. Measurements were taken for 10,000 events. Fluorescence intensity 
was normalized against the untreated controls and was expressed as per-
cent increase of mean fluorescence units.
Assessment  of  intracellular  trafficking  of  LNP-siRNAs  using  ICM.  To 
assess the intracellular distribution of encapsulated siRNA, a pulse-chase 
experiment was undertaken. BmMΦ and bmDCs were taken on day 8 of 
culture and grown on glass coverslips in 6-well plates until 70% conflu-
ent. Next, 2 μg/ml of Cy5-labeled siRNA free or encapsulated in DLinDAP, 
DLinDMA,  DLinK-DMA,  and  DLinKC2-DMA  LNPs  was  added  and 
incubated for 2 hours. Incubation was stopped by removing the media and 
washing the coverslips twice with 4 °C PBS. Fresh media was then added 
and cells were placed at 37 °C for 1, 2, 4, and 8 hours to assess the siRNA Molecular Therapy  vol. 19 no. 12 dec. 2011  2199
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distribution over time. After each time point, cells were washed in cold 
PBS, fixed with 3% paraformaldehyde for 10 minutes, permeabilized with 
0.1% saponin (Sigma, St Louis, MO), and stained with nuclear marker 
Propidium Iodide (Molecular Probes, Burlington, Canada) for 2 minutes 
to identify individual cells. After several washes, cover slips were then 
mounted onto microscope glass slides using slow fade medium (Molecular 
Probes)  and  examined  under  an  immunofluorescent  confocal  micro-
scope to assess the intracellular pattern of Cy5-labeled siRNA. Multiple 
images were captured with the ×60 objective following excitation with 
633-nm laser line. ICM was also performed to visualize the presence of 
LNP-encapsulated Cy5-siRNA in endosomes and lysosomes over various 
incubation times. For this, after 0.5, 1, 2, 4, and 8 hours of siRNA chase 
and following fixation and permeabilization, cells were stained with rabbit 
anti-Early Endosomal Antigen 1 (EEA1, Sigma). After 16-hour incuba-
tion, another set of cell-containing glass slides were costained with EEA1 
and goat anti-Lysosomal-Associated Membrane Protein 1 (LAMP1, Santa 
Cruz  Biotechnology).  Secondary  Alexa-488-conjugated  donkey  anti-
rabbit IgG (H+L) and donkey anti-goat IgG (H+L) Alexa-568 antibodies 
(Molecular Probes, OR, USA) were used to detect the endosomes and lyso-
somes, respectively. Isotype controls were used in all confocal microscopy 
experiments to confirm the specificity of antibody staining. All images 
were acquired using a Nikon-C1, TE2000-U immunofluorescent confocal 
microscope, and the EZ-C1 software. Fluorochromes were excited using 
the 488-nm, 568-nm, and 633-nm laser lines, and multiple images were 
captured using the ×60 objective.
Image  quantification:  For  consistency,  during  the  image  analysis, 
the nuclei were shown in blue and the siRNA is shown in red. EZ-C1 
3.20 FreeViewer software was used to quantify the intracellular presence 
and  distribution  of  siRNA  in  primary  bmAPCs.  For  this,  multiple 
spots of interest were drawn within the cell areas of high fluorescence 
intensity corresponding to vesicular-like compartments and areas of low 
fluorescence corresponding to cell cytoplasm. The average fluorescence 
intensity was then obtained by subtracting the background, from the high 
and low intensity values of 5–10 cells in one microscopic field. A minimum 
of three images were examined for each treatment and time point. Data 
were normalized and expressed as mean (±SD) percent of punctate or 
diffuse pattern relative to total fluorescence intensity. Colocalization of 
two molecules was analyzed using ImageJ.1 to select single slices, and 
Adobe Photoshop 9.0 CS2 was used to merge images obtained from green, 
red, and blue channels. For consistency, endosomes, lysosomes, and the 
siRNA were shown in green, blue, and red, respectively. Colocalization 
of two different molecules was evaluated by the presence, intensity, and 
distribution of the yellow color (green + red) or purple (red + blue). For 
the quantification of colocalization following dual staining, a total of ~50 
cells were examined. Absolute fluorescence intensity of green, red, blue 
and overlapping yellow and purple colors was obtained by multiplying the 
pixel value with the average intensity. The relative fluorescence intensity 
of  all  individual  colors  was  then  expressed  as  percent  of  total  green 
(endosomes) or blue (lysosomes) fluorescence. Analysis was performed 
for each of the 20 Z slices acquired, providing an overall quantification of 
colocalization for the entire cell.
In  vivo  gene  silencing  using  DLinKC2-DMA  LNPs.  All  experiments 
involving mice were performed in accordance with the requirements of 
Canadian Council and UBC Committee on Animal Care. To study the in 
vivo gene silencing properties of DLinKC2-DMA-formulated siRNA, on 
day 0, 6- to 8-week-old C57Bl6 (Charles River) triplicate mice received 
by tail vein 5 mg/kg siRNA targeting GAPDH (siGAPDH), siRNA against 
Factor VII (siFVII) as control, formulated with DLinKC2-DMA LNPs, or 
PBS. They were euthanized 4 days later to assess the gene silencing capac-
ity of siGAPDH in PerC and spleen-derived APCs. Peritoneal cavity APCs 
were obtained following peritoneal irrigation with 10 ml RPMI containing 
5% FBS and centrifugation at 1,500 for 10 minutes. Spleens were harvested, 
minced in small pieces, and digested in 1 mg/ml collagenase D (Roche) 
and CD11b+ and CD11c+ cells were isolated ex vivo using magnetic beads 
as described previously.50 Cell isolates were aliquoted, and GAPDH and 
α-Tubulin protein expression was assessed by flow cytometry as described. 
Data were acquired using LSRII flow cytometer after gating 10,000 events 
from the F4-80+/CD11b+ for MΦ or CD11chigh for DCs and analyzed by 
FlowJo software. The other aliquot of spleen-derived APCs was span down, 
lysed, and protein expression was assessed by western blotting and quanti-
fied as described earlier.
Factor VII analysis, CD45 silencing assay and GFP Longevity of   silencing. 
Both serum Factor VII silencing, CD45 surface protein level measure-
ments and 5′-RACE assay were done as described earlier.11 GFP mice (n = 
2) were injected i.v. with DLinKC2-DMA LNPs encapsulated GFP or Luc-
specific siRNA at 3 mg/kg. Peritoneal cavity MΦ were collected after 3 days 
and GFP expression was analyzed by FACS on CD11b+ cells. Remaining 
cells were plated in 96-well plate and GFP gene expression was analyzed by 
QPCR after 7, 14, and 21 days of post-injection.
TNF-α determination in vitro and in vivo. Cytokine induction by MΦ 
treated with LNP-siRNA was also studied in vitro and in vivo. BmMΦ were 
aliquoted in 48-well plates and treated with 1 and 5 μg/ml siRNA encapsu-
lated with LNPs under study. Control wells were treated with PBS or LPS 
10 ng/ml. At 2 hours, Brefeldin A (Sigma) 10 μg/ml final was added to the 
wells, and plates were returned to incubator (37 °C) for further 15 hours. 
Next, cells were washed, fixed-permeabilized, and stained with CD11b-FITC 
to detect MΦ and anti-TNF-α PE antibody (Invitrogen) to quantify the pres-
ence of TNF-α intracellularly using flow cytometry. Mice were also injected 
with siRNA formulated with DLinKC2-DMA and 72 hours later; spleen MΦ 
were isolated, aliquoted, and stimulated with 5 ng/ml PMA and 1 μg/ml iono-
mycin (Sigma) for 5 hours followed by incubation with Brefeldin A at 2-hour 
incubation. Control wells treated with PBS or LPS were also included. After 
15 hours at 37 °C, intracellular staining was performed as described to detect 
the TNF-α expression in MΦ using flow cytometry.
Statistical analysis. Student’s t-test (paired, two-sample equal variance) 
was used to compare the siRNA efficacy following delivery with formula-
tions under study as indicated. The difference was considered statistically 
significant when P < 0.05 (two-tailed distribution).
suPPleMentArY MAterIAl
Figure S1. DLinDMA is more toxic to APCs than DLinDAP, DLinK-DMA 
and DLinKC2-DMA.
Figure S2. Loss of viable cells following treatment with LNPs is due 
to apoptosis.
Figure S3. Biodistribution of LNP-siRNA and intracellular delivery in 
tissue resident APCs, B and T-cells.
Figure S4. Animals treated with DLinKC2-DMA siRNA did not show 
weight loss.
Figure S5. Gene silencing in macrophages is RNAi mediated.
Figure  S6.  In  vivo  transfected  DCs  activate  T-cells  and  migrate  in 
lymph nodes.
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